dc.identifier.uri |
http://dx.doi.org/10.15488/1158 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/1182 |
|
dc.contributor.author |
Plagemann, Thomas
|
|
dc.contributor.author |
Prenzler, Anne
|
|
dc.contributor.author |
Mittendorf, Thomas
|
|
dc.date.accessioned |
2017-02-23T13:12:54Z |
|
dc.date.available |
2017-02-23T13:12:54Z |
|
dc.date.issued |
2011 |
|
dc.identifier.citation |
Plagemann, T.; Prenzler, Anne; Mittendorf, T.: Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. In: Health Economics Review 1 (2011), Nr. 1, S. 1-9. DOI: https://doi.org/10.1186/2191-1991-1-1 |
|
dc.description.abstract |
Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders (calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in terms of binding of free phosphate. There are, however, a few disadvantages of the two groups. While the calcium-containing binders are associated with an increased risk of hypercalcaemia, which is dose dependent, calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from chronic kidney failure increases from year to year, as a result of increasing prevalence, there is a growing need for an alternative to existing phosphate binders. The study presented here therefore summarizes available information for the novel combination preparation OsvaRen® (calcium acetate/magnesium carbonate) as an alternative therapy to the calcium-free phosphate binder Renagel® (sevelamer-hydrochloride) and to calcium-containing preparations. The results of this systematic review showed that OsvaRen® is at least equally effective in the regulation of serum phosphate level as Renagel®. In particular, OsvaRen® shows no clinically relevant difference in terms of the control of the serum calcium levels compared to Renagel® and thereby does not increase the risk of a hypercalcaemia, in contrast to pure calcium-based phosphate binders. On the other hand, Renagel® therapy is much more frequently associated with gastrointestinal side-effects, a tendency to result in higher tablet burden for patients and high medication costs. The CALMAG study showed that OsvaRen® was at least as effective and safe in terms of controlling serum phosphate and serum calcium levels as Renagel® while, at the same time, resulting in about 80% lower costs. In addition, OsvaRen® offers a lower risk of hypercalcaemia and associated subsequent costs and is thereby also superior to pure calcium-containing phosphate binders. Because of the effectiveness and tolerability of calcium acetate/magnesium carbonate, OsvaRen® offers a clinically suitable and, at the same time, cost-effective therapeutic option in the therapy of hyperphosphataemia. |
eng |
dc.description.sponsorship |
Fresenius Medical Care Deutschland GmbH |
|
dc.language.iso |
eng |
|
dc.publisher |
Heidelberg : Springer Verlag |
|
dc.relation.ispartofseries |
Health Economics Review 1 (2011), Nr. 1 |
|
dc.rights |
CC BY 2.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/2.0/ |
|
dc.subject |
aluminum hydroxychloride |
eng |
dc.subject |
calci gry |
eng |
dc.subject |
calcium |
eng |
dc.subject |
calcium acetate |
eng |
dc.subject |
calcium acetate plus magnesium carbonate |
eng |
dc.subject |
calcium based phosphate binding agent |
eng |
dc.subject |
calcium carbonate |
eng |
dc.subject |
calciumacetat nefro |
eng |
dc.subject |
calciumacetat prorenal am |
eng |
dc.subject |
cc nefro |
eng |
dc.subject |
dreisacarb |
eng |
dc.subject |
lanthanum carbonate |
eng |
dc.subject |
magnesium |
eng |
dc.subject |
miscellaneous drugs and agents |
eng |
dc.subject |
osvaren |
eng |
dc.subject |
phos ex |
eng |
dc.subject |
phosphate |
eng |
dc.subject |
phosphate binding agent |
eng |
dc.subject |
sevelamer |
eng |
dc.subject |
sevelamer carbonate |
eng |
dc.subject |
unclassified drug |
eng |
dc.subject |
absence of side effects |
eng |
dc.subject |
aluminum overload |
eng |
dc.subject |
anemia |
eng |
dc.subject |
blood vessel calcification |
eng |
dc.subject |
calcium blood level |
eng |
dc.subject |
cardiovascular disease |
eng |
dc.subject |
cost benefit analysis |
eng |
dc.subject |
cost effectiveness analysis |
eng |
dc.subject |
drug cost |
eng |
dc.subject |
drug efficacy |
eng |
dc.subject |
drug safety |
eng |
dc.subject |
drug tolerability |
eng |
dc.subject |
gastrointestinal symptom |
eng |
dc.subject |
human |
eng |
dc.subject |
hypercalcemia |
eng |
dc.subject |
hyperphosphatemia |
eng |
dc.subject |
hypophosphatemia |
eng |
dc.subject |
magnesium blood level |
eng |
dc.subject |
medication compliance |
eng |
dc.subject |
monotherapy |
eng |
dc.subject |
osteomalacia |
eng |
dc.subject |
patient compliance |
eng |
dc.subject |
perception disorder |
eng |
dc.subject |
phosphate blood level |
eng |
dc.subject |
priority journal |
eng |
dc.subject |
quality of life |
eng |
dc.subject |
review |
eng |
dc.subject |
risk factor |
eng |
dc.subject |
risk reduction |
eng |
dc.subject |
systematic review |
eng |
dc.subject.ddc |
330 | Wirtschaft
|
ger |
dc.subject.ddc |
610 | Medizin, Gesundheit
|
ger |
dc.title |
Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia |
eng |
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
2191-1991 |
|
dc.relation.doi |
https://doi.org/10.1186/2191-1991-1-1 |
|
dc.bibliographicCitation.issue |
1 |
|
dc.bibliographicCitation.volume |
1 |
|
dc.bibliographicCitation.firstPage |
1 |
|
dc.bibliographicCitation.lastPage |
9 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|